The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease

This study is testing a new cell transplant treatment called NouvNeu001, where specially prepared cells are injected into the brain to try to slow or improve symptoms of Parkinson's disease. This is an early-phase safety and effectiveness study. **You may be eligible if...** - You are between 50 and 75 years old - You have a confirmed Parkinson's disease diagnosis made 4 to 20 years ago - Your motor symptoms are moderately to severely affected (Hoehn-Yahr stage 2.5 to 4 during "off" periods) - You respond well to levodopa (a standard Parkinson's medication) and score above 35 on the standard motor function scale during "off" periods - You are medically suitable for brain surgery under anesthesia **You may NOT be eligible if...** - You have atypical Parkinsonism (a different type of movement disorder) - You have had previous brain surgery including deep brain stimulation (DBS) - You have a history of severe heart or stroke disease - Brain imaging shows abnormalities that increase surgery risk - You have a history of cancer Talk to your doctor to see if this trial is right for you.